News Release
16 avril 2013
|
Mayer Brown, a leading global law firm, secured a victory before the US Court of Appeals for the Federal Circuit on behalf of Glaxo Group Ltd. and GlaxoSmithKline (GSK) in a patent infringement suit brought by Biogen Idec Inc. and Genentech Inc. In the suit, the plaintiffs alleged that GSK’s monoclonal antibody cancer treatment, ARZERRA®, infringed their patent relating to the treatment of chronic lymphocytic leukemia (CLL) through administration of an anti-CD20 antibody. ARZERRA® is the first FDA approved fully human monoclonal antibody for the treatment of CLL and competes with Genentech’s cancer treatment Rituxan®.
|
Legal Update
15 avril 2013
|
Mayer Brown Legal Update
The US Federal Communications Commission (FCC or Commission) recently released an Order, Further Notice of Rulemaking (Further Notice) and Notice of Inquiry (NOI) on radio frequency (RF) exposure limits and policies.
|
Media Coverage
8 avril 2013
|
Law360
Litigation & Dispute Resolution partner Hank Bullock (New York) is profiled in a Law360 Q&A feature.
|
|
|
Mayer Brown Newsletter
This is a short guide to some of the key legal developments for intellectual property in the life sciences sector in 2013.
|
|
|
Mayer Brown Newsletter
This is a short guide outlining some of the key legal developments in the life sciences sector in 2013.
|
Legal Update
19 March 2013
|
Mayer Brown Legal Update
The UK Supreme Court has unanimously ruled on an important commercial activity for patentees and spare part manufacturers, namely when supplying replacement parts constitutes patent infringement. The decision also deals with the consequences of failing to register a patent licence.
The decision has potentially significant strategic implications for both patent litigation and the question of infringement, and for commercial transactions that require recordal of patent licences and the consequences of failing to do so.
|
Legal Update
13 février 2013
|
Mayer Brown Legal Update
A new rule has imposed reporting requirements on certain manufacturers of drugs, devices, and biological or medical supplies, as well as on group purchasing organizations (GPOs) concerning certain financial dealings with physicians and teaching hospitals.
|
Newsletter
11 février 2013
|
Mayer Brown Newsletter
This is a short guide outlining some of the key legal developments in the life sciences sector in 2013. |
|
|
FORUM · Institut für Management GmbH
This article provides the reader with a compact legal update on the regulatory and legal framework of the off-label-use of drugs in Germany. The off-label use of drugs is a wide-spread and important medical and legal phenomenon. The article examines when such off-label use is permitted by the applicable laws and further provides an overview of the legal aspects related to product liability, drug advertising, drug information and reimbursement of off-label use.
|
Legal Update
28 janvier 2013
|
Mayer Brown Legal Update
Recent legislative and administrative activities have further changed, and improved on, the implementation of the patent laws under the Leahy-Smith America Invents Act (AIA).
|
Legal Update
21 janvier 2013
|
Mayer Brown Legal Update
This is a short guide to some of the key legal developments for intellectual property in the life sciences sector in 2013.
The developments include a proposed new EU Clinical Trials Regulation, progress of the EU unitary patent package, the UK Patent Box and R&D tax credit coming into effect, reform of the research and Bolar exceptions and a proposed new EU legislative framework for medical devices. They also include developments relating to database rights, exceptions to copyright law, changes to UK design law and a new EU Regulation on data protection.
|
Legal Update
21 janvier 2013
|
Mayer Brown Legal Update
This is a short guide to some of the key legal developments for intellectual property and data protection in 2013.
The developments include proposed changes to copyright law following consultation in 2012, new copyright exceptions, extension of copyright protection for sound recordings, new remedies for UK-registered design owners against innocent infringement, progress of the EU unitary patent package, the UK Patent Box and R&D tax credit coming into effect, the introduction of binding corporate rules for data processors and progress of the proposed new EU Regulation on data protection.
|
|
|
|
|
|
|
|
|
MPR 2012, pp. 158-165
Article looks at the German product liability scheme for the medical devices liability and discusses current issues related to the liability for implantable medical devices like pacemakers.
|
Legal Update
3 décembre 2012
|
Mayer Brown Legal Update
The English Patents Court has delivered a ground-breaking judgment which could change the way that European patent litigation is conducted. It has significant strategic implications for companies involved in pan-European patent litigation, or who are crafting such strategies.
|
Media Coverage
November 2012
|
World Intellectual Property Report
Bylined article by London Intellectual Property partner Jonathan Radcliffe on national patent litigation in Europe and the interface with EPO Oppositions. This is the fifth of a six-part series.
This article first appeared in Bloomberg BNA's World Intellectual Property Report and is reproduced with their kind permission.
|
Media Coverage
October 2012
|
For the Defense
A bylined article by Litigation & Dispute Resolution partner Hank Bullock and associate Andrew Calica (both New York) discusses legal, regulatory and economic uncertainties in the up-and-coming biosimilar marketplace.
|
Media Coverage
October 2012
|
For the Defense
A bylined article by Litigation & Dispute Resolution partner Andrew Tauber and associate Brian Wong (both Washington, DC) explains how to argue medical device preemption and discusses best practices and pitfalls to avoid.
|
Media Coverage
October 2012
|
World Intellectual Property Report
Bylined article by London Intellectual Property partner Jonathan Radcliffe on the importance of patent term extensions. This is the fourth of a six-part series.
This article first appeared in Bloomberg BNA's World Intellectual Property Report and is reproduced with their kind permission.
|
Legal Update
27 septembre 2012
|
Mayer Brown Legal Update
The European Patent Office Technical Board of Appeal has ruled on what is increasingly an important component of the evidence forming prior art attacks, namely alleged disclosures by email. The precedent-conferring status of the TBA means that this is a significant decision both for EPO oppositions and for litigation in national courts across Europe.
|
|
|
World Intellectual Property Report
Bylined article by London Intellectual Property partner Jonathan Radcliffe and German Intellectual Property partner Dr. Ulrich Worm on the strategic and planning considerations for patent litigation in Europe. This is the third of a six-part series.
This article first appeared in Bloomberg BNA's World Intellectual Property Report and is reproduced with their kind permission.
|
|
|
Mayer Brown, a leading global law firm, announced today that the 2012 edition of Chambers Europe: Europe’s Leading Lawyers for Business ranked the firm in 23 geographic and/or practice categories in Belgium, France, Germany and the United Kingdom, including two top-band rankings.
|
Legal Update
10 février 2012
|
Mayer Brown Legal Update
The US Food and Drug Administration has issued three draft guidance documents regarding biosimilars (a/k/a follow-on biologics). The documents describe key scientific and regulatory factors involved in submitting applications for biosimilar products for agency approval (351(k) applications). We review the key elements of each and provide links to the full text of the three guidance documents.
|
Legal Update
February 2012
|
Mayer Brown Legal Update
On 6 December 2011, the UK Government released draft legislation detailing its proposal to introduce from 1 April 2013 an optional preferential regime providing for a reduced 10% UK corporation tax rate for profits arising from patents (and other limited forms of qualifying IP, such as rights pertaining to the regulatory data protection granted to new pharmaceuticals and agrochemical products and plant variety rights).
|